Results 231 to 240 of about 28,830 (241)

Population Pharmacokinetics of Efavirenz in an Unselected Cohort of HIV-1-Infected Individuals

Clinical Pharmacokinetics, 2012
Bregt S Kappelhoff, Jan M Prins, Jan W Mulder   +2 more
exaly  

Impact of efavirenz pharmacokinetics and pharmacogenomics on neuropsychological performance in older HIV-infected patients

Journal of Antimicrobial Chemotherapy, 2017
Uriel Sandkovsky, Anthony T Podany, Courtney V Fletcher   +2 more
exaly  

Lipid Changes in Patients Initiating Efavirenz- and Indinavir-Based Antiretroviral Regimens

HIV Clinical Trials, 2003
Flanigan Timothy P, Karen T Tashima, Timothy P Flanigan   +2 more
exaly  

Induction of CYP3A4 by Efavirenz in Primary Human Hepatocytes: Comparison With Rifampin and Phenobarbital

Journal of Clinical Pharmacology, 2004
Arthur R Buckley, Pankaj B Desai
exaly  

Efavirenz

Inpharma Weekly, 1999
openaire   +1 more source

Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition

Antimicrobial Agents and Chemotherapy, 2017
Jason Robarge, Íngrid F Metzger, Todd C Skaar   +2 more
exaly  

CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans

European Journal of Clinical Pharmacology, 2011
Kazuma Kiyotani, Collen Masimirembwa, Yusuke Nakamura   +2 more
exaly  

Dependence of Efavirenz- and Rifampicin-Isoniazid–Based Antituberculosis Treatment Drug-Drug Interaction on CYP2B6 and NAT2 Genetic Polymorphisms: ANRS 12154 Study in Cambodia

Journal of Infectious Diseases, 2014
Julie Bertrand, Celine Verstuyft, Monidarin Chou   +2 more
exaly  

Efavirenz

Reactions Weekly, 2001
openaire   +1 more source

Unmasking efavirenz neurotoxicity: Time matters to the underlying mechanisms

European Journal of Pharmaceutical Sciences, 2017
Nadia M Grilo, Joana P Miranda, Madalena Cipriano   +2 more
exaly